A5014332786- RNA Interference and Gene Delivery
- Nanoplatforms for cancer theranostics
- Immunotherapy and Immune Responses
- Advanced biosensing and bioanalysis techniques
- Nanoparticle-Based Drug Delivery
- Virus-based gene therapy research
- Graphene and Nanomaterials Applications
- Advanced Drug Delivery Systems
- Lipid Membrane Structure and Behavior
- 3D Printing in Biomedical Research
- Immune Response and Inflammation
- Cervical Cancer and HPV Research
- Advancements in Transdermal Drug Delivery
- Photodynamic Therapy Research Studies
- Monoclonal and Polyclonal Antibodies Research
- MicroRNA in disease regulation
- Viral Infectious Diseases and Gene Expression in Insects
- Hepatitis B Virus Studies
- Drug Solubulity and Delivery Systems
- Bacteriophages and microbial interactions
- Helicobacter pylori-related gastroenterology studies
- Viral gastroenteritis research and epidemiology
- Immune Cell Function and Interaction
- Liver physiology and pathology
- CRISPR and Genetic Engineering
Seoul National University
2016-2025
Redcliffe Hospital
2024
Government of the Republic of Korea
2015-2020
Seoul Institute
2020
Purdue University West Lafayette
2020
Center for Cancer Research
2020
Instytut Farmaceutyczny
2015
Samsung Medical Center
2012
Weatherford College
2011
Korea Institute of Science and Technology
2004-2010
Abstract Chimeric antigen receptor‐T (CAR‐T) cell immunotherapy has shown impressive clinical outcomes for hematologic malignancies. However, its broader applications are challenged due to complex ex vivo cell‐manufacturing procedures and low therapeutic efficacy against solid tumors. The limited effects partially CAR‐T infiltration tumors inactivation of cells by the immunosuppressive tumor microenvironment. Here, a facile approach is presented in program macrophages, which can...
A novel target specific small interfering RNA (siRNA) delivery system was successfully developed using polyethyleneimine (PEI)-hyaluronic acid (HA) conjugate. Anti-PGL3-Luc siRNA used as a model suppressing the PGL3-Luc gene expression. The siRNA/PEI-HA complex with an average size of ca. 21 nm appeared to be formed by electrostatic interaction between negatively charged and positively PEI PEI-HA cytotoxicity B16F1 cells lower than that siRNA/PEI according MTT assay. When HEK-293 were...
Despite the progress of conventional vaccines, improvements are clearly required due to concerns about weak immunogenicity these intrinsic instability in vivo, toxicity, and need for multiple administrations. To overcome such problems, nanotechnology platforms have recently been incorporated into vaccine development. Nanocarrier-based delivery systems offer an opportunity enhance humoral cellular immune responses. This advantage is attributable nanoscale particle size, which facilitates...
Although immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy, monotherapy approach is not sufficient. Here, we report an inhibitor-modified nanoparticle for situ-assembled tumor vaccine that can activate systems the microenvironment and prevent long-term recurrence of tumors. Adjuvant-loaded nanoparticles were prepared by entrapping imiquimod (IQ) photoresponsive polydopamine (IQ/PNs). The surfaces IQ/PNs then modified with anti-PDL1 antibody (PDL1Ab-IQ/PNs) situ...
Nucleic acid-based bioactive substances have recently emerged as a new class of next-generation therapeutics, but their development has been limited by relatively weak delivery into target cells. Cationic liposomes studied means to enhance the stability nucleic acid therapeutics in bloodstream and improve cellular delivery. As siRNA plasmid DNA extensively tested for using cationic liposomes. This review discusses recent progress application therapeutics.